

Date: 19<sup>th</sup> June, 2020

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Tower, Dalal Street,  
Fort, Mumbai - 400 001

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its General Oral Solid Formulation Facility (F-I) at Panelav**

**Ref.: Our earlier intimation dated 4<sup>th</sup> May, 2020 - Voluntary Action Indicated (VAI) by USFDA**

We would like to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our General Oral Solid Formulation Facility (F-I) at Panelav during the period from 9<sup>th</sup> March, 2020 to 13<sup>th</sup> March, 2020.

With this, EIR is in place for all our manufacturing facilities for international markets.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**



**Charandeep Singh Saluja**  
Company Secretary

**ALEMBIC PHARMACEUTICALS LIMITED**